PHARMACOKINETICS OF SIMEPREVIR (TMC435) IN VOLUNTEERS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT

被引：13
|
作者：
Ouwerkerk-Mahadevan, S. [1 ]
Simion, A. [2 ]
Spittaels, K. [2 ]
Beumont-Mauviel, M. [2 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Infect Dis BVBA, Beerse, Belgium
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60889-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
887
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
    Sekar, V.
    Simion, A.
    Peeters, M.
    Spittaels, K.
    Lawitz, E.
    Marbury, T. C.
    De Smedt, G.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S193 - S193
  • [2] ABSENCE OF PHOTOSENSITIVITY POTENTIAL OF TMC435 IN HEALTHY VOLUNTEERS
    Simion, A.
    Janssens, L.
    Peeters, M.
    Ouwerkerk-Mahadevan, S.
    Spittaels, K.
    De Smedt, G.
    Akuma, S. H.
    Beumont-Mauviel, M.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S458 - S458
  • [3] COMBINATION THERAPY OF TMC647055 WITH SIMEPREVIR (TMC435) IN CHRONIC HEPATITIS C PATIENTS
    Bourgeois, S.
    Reesink, H. W.
    Leempoels, J.
    Vijgen, L.
    Rouan, M. -C.
    Marien, K.
    Van Remoortere, P.
    Fanning, G.
    Picchio, G.
    Simmen, K.
    Verloes, R.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S483 - S483
  • [4] Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
    Rosenquist, Asa
    Samuelsson, Bertil
    Johansson, Per-Ola
    Cummings, Maxwell D.
    Lenz, Oliver
    Raboisson, Pierre
    Simmen, Kenny
    Vendeville, Sandrine
    de Kock, Herman
    Nilsson, Magnus
    Horvath, Andras
    Kalmeijer, Ronald
    de la Rosa, Guy
    Beumont-Mauviel, Maria
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1673 - 1693
  • [5] IN VITRO STUDIES INVESTIGATING THE MECHANISM OF INTERACTION BETWEEN TMC435 AND HEPATIC TRANSPORTERS
    Huisman, Maarten T.
    Snoeys, Jan
    Monbaliu, Johan
    Martens, Mark A.
    Sekar, Vanitha J.
    Raoof, Araz
    [J]. HEPATOLOGY, 2010, 52 (04) : 461A - 462A
  • [6] EFFECT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON CLARITHROMYCIN PHARMACOKINETICS
    CHU, SY
    GRANNEMAN, GR
    PICHOTTA, PJ
    DECOURT, JP
    GIRAULT, J
    FOURTILLAN, JB
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (05): : 480 - 485
  • [7] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [8] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    [J]. Critical Care, 12 (Suppl 2):
  • [9] EVALUATION OF METABOLIC INTERACTIONS FOR TMC435 VIA CYTOCHROME P450 (CYP) ENZYMES IN HEALTHY VOLUNTEERS
    Sekar, V.
    Verloes, R.
    Meyvisch, P.
    Spittaels, K.
    Akuma, S. H.
    De Smedt, G.
    [J]. JOURNAL OF HEPATOLOGY, 2010, 52 : S416 - S416
  • [10] Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
    Venkatakrishnan, Karthik
    Liu, Yi
    Noe, Dennis
    Mertz, Jaime
    Bargfrede, Michael
    Marbury, Thomas
    Farbakhsh, Kambiz
    Oliva, Cristina
    Milton, Ashley
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 998 - 1010
12345